Original Publication Date: 1 June, 2014
Publication / Source: Personalized Medicine
Authors: Isaac J Powell, Gregory Dyson, Sreenivasa R Chinni, Aliccia Bollig-Fischer
Genomic rearrangement and overexpression of the ERG oncogene (also known as v-ets avian erythroblastosis virus E26 oncogene homolog) is estimated to occur at a rate of 40–50% in prostate cancer. Early evidence suggests that ERG overexpression may be associated with disease progression, and the utilization of ERG levels as a biomarker for prostate cancer is being strongly considered.